Probiotics for Treating Metabolic Disorders

Nanocapsule-based drug delivery system to reduce uric acid levels in the body for treating gout and hyperuricemia. It involves oral administration of nanocapsules containing mRNA that encodes uricase enzyme. The mRNA is encapsulated in virus-like particles (VLPs) created by self-assembling capsid proteins. The VLPs protect the mRNA while being delivered to cells. The mRNA is expressed to produce uricase enzyme that breaks down uric acid. This provides an oral, non-allergenic therapy for gout and hyperuricemia.

Source

Diagnostic and therapeutic methods for muscle wasting. The methods involve analyzing quorum sensing molecules (QSMs) in a sample to diagnose muscle wasting and using bacterial strains that do not produce harmful QSMs to prevent and treat muscle wasting.

Source

Using Bacillus Calmette-Guerin (BCG) to treat diabetes, particularly type 1 diabetes, and methods to identify individuals who are likely to benefit from BCG treatment.

Source

Microbial consortia for effectively treating conditions related to metabolic disease by efficiently breaking down and metabolizing disease-associated substrates. The consortia contain a group of active microbes that degrade the substrate causing the disease, along with a supportive community of microbes that optimize the active microbes' growth and metabolism. The supportive community enhances characteristics like engraftment, biomass, stability of the active microbes. The consortium can degrade substrates like phenylalanine, tyrosine, bile acids, and pathogenic carbohydrates.

Source

Using inactivated Lactobacillus casei I0B-P9 and its postbiotics to reduce blood glucose and improve dyslipidemia in diabetics.

Source

Compositions comprising Oxalobacter formigenes (Of)-derived factors and variants and fragments thereof, and method of use thereof for the treatment/prevention of excess oxalate levels and conditions and diseases related thereto. The Of-derived factors, including peptides and polypeptides, stimulate oxalate transport and can be used to treat hyperoxaluria, hyperoxalemia, and related conditions.

Source

A method for treating type 2 diabetes (T2D) by modulating a subject's microbiota composition away from that associated with a Western diet and toward one conferring the benefits of a plant-based diet. The method involves administering probiotics and prebiotics to improve the gut microbiome, with strains shown to be beneficial in studies of diabetes and obesity. The microbial compositions can be customized based on an individual's microbiome profile and contain specific bacteria and fungi identified from plants.

Source

Regulating expression of genes involved in gout using Lactobacillus plantarum bacteria. The method involves administering an effective amount of inactivated Lactobacillus plantarum cells to a subject with gout to reduce inflammation. The Lactobacillus plantarum strain downregulates expression of interleukin-1β (IL-1β) and MMP1a genes, while upregulating TIMP1 gene expression in chondrocytes.

Source

Using a specific strain of Lactobacillus rhamnosus called CMU-pb-7 isolated from feces, to prepare blood lipid-lowering drugs. The strain can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet.

Source

Food or pharmaceutical compositions with specific strains of lactic acid bacteria (Lactobacillus fermentum TSF331 and Lactobacillus reuteri TSR332) that can be used to reduce blood uric acid concentration. The compositions can be administered to help prevent and treat conditions like hyperuricemia and gout. The compositions contain strains that have been shown to degrade purine and lower uric acid levels.

Source

Compositions and methods for treating type 1 diabetes using genetically modified lactic acid bacteria expressing IL-2 and a type 1 diabetes-specific antigen. The bacteria are orally administered to deliver low-dose IL-2 and antigen to the gut mucosa, stimulating regulatory T cells to suppress autoimmunity and reverse established type 1 diabetes.

Source

Genetically engineered bacteria that can reduce hyperphenylalaninemia in mammals like humans. The bacteria are designed to produce a modified version of the enzyme phenylalanine ammonia lyase (PAL) that better metabolizes phenylalanine. This allows the bacteria to break down excess phenylalanine in the gut and reduce blood levels. It could offer a novel treatment option for phenylketonuria (PKU) and other disorders associated with high phenylalanine. The engineered bacteria may be orally administered to provide a long-term, natural protein-friendly approach to reducing phenylalanine.

Source

Compositions containing a mixture of microorganisms like bacteria, yeasts, and fungi for reducing blood urate levels as a treatment and prevention strategy for urate-related diseases like gout and hyperuricemia. The compositions aim to balance the gut microbiota by increasing uricase activity and reducing xanthine oxidase activity. This can be achieved using specific strains that inhibit xanthine oxidase and/or express uricase.

Source

A Lactobacillus plantarum strain that can lower blood glucose levels and has antioxidant activity. It's used in compositions like food, medical, and cosmetic products to help prevent and treat diabetes and provide antioxidant benefits. The strain, Lactobacillus plantarum MG4229, is isolated from food and has characteristics like acid and bile tolerance, hydrophobicity, and enzyme production.

Source

Bacterial compositions and extracts for treating diseases related to mitochondrial dysfunction. The compositions contain specific bacteria species that enhance mitochondrial function and ATP production when administered to a subject. The bacteria express enzymes like glucose dehydrogenase and iron-sulfur reductase that promote cellular energy production.

Source

A composition for preventing and treating lipid-related metabolic diseases such as fatty liver, diabetes, and obesity. It contains Lactobacillus plantarum ATG-K2 or ATG-K6 strains isolated from fermented vegetables. The composition can be used as a health supplement or functional food to improve markers of liver health, lipid metabolism, obesity, and diabetes. It provides a natural and effective treatment option for lipid-related metabolic disorders.

Source

Using certain bacteria and their metabolites to prevent or treat inflammation-related diseases like diabetes, autoimmune conditions, cardiovascular disease, and inflammatory disorders. The specific bacteria are Desulfovibrio species like Desulfovibrio piger, and the metabolites include 6-bromotryptophan. Administering these agents can reduce inflammation and severity of these diseases.

Source

Probiotic compositions and methods for improving metabolic health and preventing obesity related disorders. The compositions contain specific strains of gut bacteria including Eubacterium eligens, Intestinimonas massiliensis, Prevotella copri, and certain Akkermansia species. Administering these compositions can help treat or prevent obesity, diabetes, metabolic syndrome and related conditions.

Source

Microorganisms and extracts thereof that reduce liver fat content, inhibit lipogenesis, promote fat oxidation, reduce body fat, and increase AMPK phosphorylation when contacted with liver or fat cells. The microorganisms are Lactobacillus strains LMT15-14 and LMT19-1.

Source

Feeding infants a nutritional composition containing Bifidobacterium breve and non-digestible oligosaccharides early in life to prevent metabolic disorders like fatty liver disease, hypercholesterolemia, and atherosclerosis later in life. The composition promotes healthy lipid metabolism and liver function when challenged with a high fat diet by modulating gene expression pathways. The Bifidobacterium breve probiotic and oligosaccharides combination can be added to infant formula to mimic breast milk benefits for long-term metabolic health.

Source